{"schema_version":"secwatch.filing_event.v1","accession":"0001035267-26-000047","form_type":"8-K","ticker":"ISRG","cik":"0001035267","company_name":"INTUITIVE SURGICAL INC","filed_at":"2026-07-16T20:05:17+00:00","discovered_at":"2026-07-16T20:06:00.243579+00:00","generated_at":"2026-07-16T20:06:14.969238+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Intuitive Surgical Q2 revenue $2.89B (+19% YoY); GAAP EPS $2.29, non-GAAP $2.80","bullets":["Worldwide procedures grew ~16% (da Vinci +15%, Ion +36%); 468 da Vinci systems placed (246 da Vinci 5).","GAAP net income $818M ($2.29/diluted share) vs $658M ($1.81) YoY; non-GAAP net income $1.00B ($2.80).","Q2 included $28M net benefit from IEEPA tariff refunds; repurchased 0.9M shares for $0.38B.","FY2026 guidance: da Vinci procedure growth ~13.5%-15.5% (closer to midpoint); non-GAAP gross margin 68%-69%.","Non-GAAP operating expense growth guided at 11%-13%; tariff impact estimated at 1% of revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001035267-26-000047","json":"https://secwatch.observer/filing/0001035267-26-000047.json","markdown":"https://secwatch.observer/filing/0001035267-26-000047.md","text":"https://secwatch.observer/filing/0001035267-26-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035267/000103526726000047/0001035267-26-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035267/000103526726000047/isrg-20260716.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-16T20:06:14.969238+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}